Free Trial
NASDAQ:HYPR

Hyperfine (HYPR) Stock Price, News & Analysis

$0.86
-0.05 (-5.49%)
(As of 05/23/2024 ET)
Today's Range
$0.84
$0.95
50-Day Range
$0.79
$1.19
52-Week Range
$0.76
$3.28
Volume
171,357 shs
Average Volume
77,567 shs
Market Capitalization
$61.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.12

Hyperfine MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
145.8% Upside
$2.12 Price Target
Short Interest
Bearish
2.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of Hyperfine in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2,423 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.53) to ($0.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.23 out of 5 stars

Medical Sector

506th out of 915 stocks

Electromedical Equipment Industry

12th out of 19 stocks

HYPR stock logo

About Hyperfine Stock (NASDAQ:HYPR)

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

HYPR Stock Price History

HYPR Stock News Headlines

Hyperfine, Inc. Celebrates ASNR 2024
Recap: Hyperfine Q4 Earnings
Hyperfine Inc Class A HYPR
HYPR/USD - Hypr Network US Dollar
See More Headlines
Receive HYPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hyperfine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
5/23/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:HYPR
Fax
N/A
Employees
131
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.12
High Stock Price Target
$3.50
Low Stock Price Target
$1.25
Potential Upside/Downside
+145.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-44,240,000.00
Net Margins
-358.59%
Pretax Margin
-358.59%

Debt

Sales & Book Value

Annual Sales
$11.03 million
Book Value
$1.05 per share

Miscellaneous

Free Float
50,782,000
Market Cap
$61.95 million
Optionable
Optionable
Beta
0.82
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. R. Scott Huennekens CPA (Age 60)
    M.B.A., Executive Chairman
    Comp: $1.29M
  • Ms. Maria Sainz (Age 58)
    CEO, President & Director
    Comp: $340.24k
  • Dr. Jonathan M. Rothberg Ph.D. (Age 60)
    Founder & Vice Chairman
    Comp: $51.37k
  • Mr. Brett Hale (Age 50)
    Chief Administrative Officer, CFO, Chief Compliance Officer, Treasurer & Corporate Secretary
  • Dr. Thomas Teisseyre Ph.D.
    Chief Operating Officer
  • Mr. Chip Truwit FACR
    M.D., Vice President of Scientific Affairs

HYPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Hyperfine stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hyperfine in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" HYPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HYPR, but not buy additional shares or sell existing shares.
View HYPR analyst ratings
or view top-rated stocks.

What is Hyperfine's stock price target for 2024?

3 brokers have issued twelve-month target prices for Hyperfine's shares. Their HYPR share price targets range from $1.25 to $3.50. On average, they anticipate the company's stock price to reach $2.12 in the next twelve months. This suggests a possible upside of 145.8% from the stock's current price.
View analysts price targets for HYPR
or view top-rated stocks among Wall Street analysts.

How have HYPR shares performed in 2024?

Hyperfine's stock was trading at $1.12 at the start of the year. Since then, HYPR shares have decreased by 23.1% and is now trading at $0.8610.
View the best growth stocks for 2024 here
.

When is Hyperfine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our HYPR earnings forecast
.

How were Hyperfine's earnings last quarter?

Hyperfine, Inc. (NASDAQ:HYPR) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02. The firm had revenue of $2.69 million for the quarter, compared to analyst estimates of $3.66 million. Hyperfine had a negative net margin of 358.59% and a negative trailing twelve-month return on equity of 46.96%.

What guidance has Hyperfine issued on next quarter's earnings?

Hyperfine issued an update on its FY 2024 earnings guidance on Monday, May, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $12.0 million-$15.0 million, compared to the consensus revenue estimate of $12.8 million.

How do I buy shares of Hyperfine?

Shares of HYPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HYPR) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners